{"id":"NCT06460493","sponsor":"Verona Pharma plc","briefTitle":"Effect of Ensifentrine Treatment on CAT Score","officialTitle":"A Study Assessing the Effect of Ensifentrine on CAT™ Scores Over 12 Weeks in Subjects With Moderate to Severe COPD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2024-06-11","primaryCompletion":"2024-11-26","completion":"2024-12-03","firstPosted":"2024-06-14","resultsPosted":"2025-04-18","lastUpdate":"2025-04-18"},"enrollment":20,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["COPD"],"interventions":[{"type":"DRUG","name":"Ensifentrine 3 mg twice daily","otherNames":["RPL554"]}],"arms":[{"label":"Ensifentrine","type":"EXPERIMENTAL"}],"summary":"The purpose of this open-label, single center trial is to assess the effect of twice daily nebulized ensifentrine (3 mg) on COPD symptoms measured by the COPD Assessment Test (CAT™) scores over 12 weeks in subjects with symptomatic, moderate to severe COPD, taking maintenance LAMA/LABA or LAMA/LABA/ICS therapy. Subjects will continue the maintenance treatment during study participation.","primaryOutcome":{"measure":"The Proportion of CAT Score Responders in the Full Analysis Set at Week 12","timeFrame":"12 Weeks","effectByArm":[{"arm":"Ensifentrine 3 mg BID","deltaMin":12,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":[]}}